Ultromics推出用于EchoGo®心力衰竭的AI驱动概率评分以增强HFpEF诊断-动脉网

Ultromics Introduces AI-Powered Probability Scoring on EchoGo® Heart Failure for Enhanced HFpEF Diagnosis

CISION 等信源发布 2025-03-28 21:00



可切换为仅中文







OXFORD, England

牛津，英格兰

，

March 28, 2025

2025年3月28日

/PRNewswire/ --

Ultromics

超声心动图分析系统

, a pioneer in AI-driven cardiology solutions, has unveiled the latest enhancement to EchoGo® Heart Failure: the introduction of a first-of-its-kind AI-powered probability scoring system for assessing heart failure with preserved ejection fraction (HFpEF). This innovation marks a groundbreaking development the use of deep learning to improve the detection of this often underrecognized condition..

，一家人工智能驱动的心脏病学解决方案的先驱，公布了EchoGo® 心力衰竭的最新改进：推出了首个用于评估射血分数保留型心力衰竭（HFpEF）的基于人工智能的概率评分系统。这一创新标志着使用深度学习来改善这种经常被低估的疾病的检测取得了突破性进展。

继续阅读

Ultromics Introduces AI-Powered Probability Scoring on EchoGo® Heart Failure for Enhanced HFpEF Diagnosis

Ultromics 推出基于人工智能的概率评分系统，用于 EchoGo® 心力衰竭，以提升 HFpEF 的诊断效果。

EchoGo® Heart Failure remains the first and only AI platform capable of identifying HFpEF from a routine echocardiogram. The new probability scoring system builds upon this unique capability by generating a continuous score of the likelihood of disease, which provides a more nuanced diagnostic assessment of HFpEF, minimizing uncertainty and enhancing clinical decision-making.

EchoGo® 心力衰竭仍然是首个且唯一能够通过常规超声心动图识别HFpEF的AI平台。新的概率评分系统基于这一独特能力，生成疾病可能性的连续评分，从而提供更细致的HFpEF诊断评估，减少不确定性并增强临床决策。

Additionally, the platform continues to support the detection of other critical heart conditions, such as cardiac amyloidosis, helping clinicians in the early identification of underlying causes of heart failure..

此外，该平台还持续支持对其他严重心脏状况的检测，例如心脏淀粉样变性，帮助临床医生早期识别心力衰竭的根本原因。

'The introduction of the probability scoring feature into the EchoGo® Heart Failure platform represents a pivotal step forward in heart failure detection and patient risk stratification,' said

“将概率评分功能引入EchoGo®心力衰竭平台，标志着在心力衰竭检测和患者风险分层方面迈出了关键一步，”

Ross Upton

罗斯·厄普顿

, PhD, Founder, CEO, and Chief Scientific Officer of Ultromics. 'By delivering a precise probability score, EchoGo® Heart Failure enables clinicians to assess a patient's likelihood of disease, allowing for more confident decision-making'.

博士，Ultromics创始人、首席执行官兼首席科学官。‘通过提供精确的概率评分，EchoGo® 心力衰竭使临床医生能够评估患者患病的可能性，从而做出更有信心的决策。’

Real-World Impact and Clinical Validation

真实世界影响与临床验证

The updated EchoGo® Heart Failure platform has been rigorously validated in a study at Beth Israel Deaconess Medical Center (BIDMC), a

更新后的 EchoGo® 心力衰竭平台在贝丝以色列女执事医疗中心 (BIDMC) 的一项研究中得到了严格验证，

Harvard Medical School

哈佛医学院

teaching hospital, and other leading clinical sites. This study focused on real-world, complex cases, including patients with multiple overlapping comorbidities, such as a combination of hypertension and diabetes, where traditional diagnostic models may struggle to distinguish between cases and controls effectively..

教学医院和其他领先的临床站点。该研究聚焦于现实世界中的复杂病例，包括患有多种重叠并发症的患者，例如高血压和糖尿病的组合，传统诊断模型可能难以有效区分病例和对照组。

Results revealed that the AI-powered probability scoring system provides substantial added information, accurately aiding in the diagnosis of HFpEF, the likelihood of disease, and patient outcomes. The platform demonstrated higher sensitivity in detecting HFpEF and improved differentiation between HFpEF and clinically complex controls at risk or with possible—but not confirmed—HFpEF, compared to standard clinical practice..

结果显示，人工智能驱动的概率评分系统提供了重要的附加信息，准确帮助诊断HFpEF、疾病的可能性及患者预后。与标准临床实践相比，该平台在检测HFpEF方面显示出更高的敏感性，并改善了HFpEF与有风险或可能但未确诊的HFpEF的临床复杂对照组之间的区分。

[1]

The new probability scoring feature also associates positively to patient outcomes: patients flagged by EchoGo® Heart Failure as high-risk showed a two-fold increase in the likelihood of heart failure hospitalizations and mortality, highlighting the potential of AI to inform timely interventions that could improve patient management..

新的概率评分功能也与患者预后呈正相关：被EchoGo®心力衰竭标记为高风险的患者，其心力衰竭住院和死亡的可能性增加了两倍，突显了人工智能在指导及时干预方面的潜力，从而改善患者管理。

[1]

Using all available clinical information with EchoGo® Heart Failure led to a 33% improvement in correctly managing patients with HFpEF, compared to relying solely on the H2FPEF score.

使用EchoGo®心力衰竭结合所有可用的临床信息，相比仅依赖H2FPEF评分，正确管理HFpEF患者的能力提升了33%。

[1]

When compared to standard clinical practice, like H2FPEF and HFA-PEFF, EchoGo® Heart Failure demonstrated fewer indeterminate classifications, reducing diagnostic uncertainty—a common issue with traditional models—leading to confident diagnoses in over 80% of patients.

与标准临床实践（如H2FPEF和HFA-PEFF）相比，EchoGo® Heart Failure展示了更少的不确定分类，减少了诊断不确定性——这是传统模型常见的问题——在超过80%的患者中实现了可靠的诊断。

[1]

'By integrating this advanced AI-powered tool into routine echocardiograms, we are enhancing our ability to detect HFpEF with greater certainty,' said

“通过将这种先进的AI驱动工具整合到常规超声心动图中，我们能够以更高的确定性检测HFpEF，”他表示。

Jordan Strom

乔丹·斯特罗姆

, lead study author and cardiologist at Beth Israel Deaconess Medical Center, a teaching hospital of

，首席研究作者、贝斯以色列女执事医疗中心的心脏病专家，该中心是

Harvard Medical School

哈佛医学院

. 'This is especially important in a disease as heterogeneous as HFpEF. Our work suggests that the combination of clinical scores and AI may improve certainty about the diagnosis of HFpEF and suggests a possible path forward for the integration of AI into clinical practice. This approach can ultimately help ensure timely recognition and treatment of HFpEF and facilitate clinical workflows.'.

“这在像HFpEF这样异质性很强的疾病中尤为重要。我们的工作表明，临床评分与人工智能的结合可能会提高对HFpEF诊断的确定性，并为将人工智能整合到临床实践中提供了一条可能的路径。这种方法最终有助于确保及时识别和治疗HFpEF，并优化临床工作流程。”

Introducing the Probability Score Enhancement

引入概率评分增强功能

HFpEF remains one of the most challenging forms of heart failure to diagnose partly due to the complex interplay between multiple clinical and echocardiographic parameters. Accurate detection requires the careful integration of these variables, which can be discordant or indeterminate in some patients.

HFpEF仍然是最具挑战性的心力衰竭诊断形式之一，部分原因是多个临床和超声心动图参数之间的复杂相互作用。准确的检测需要仔细整合这些变量，在某些患者中这些变量可能是不一致或不确定的。

As a result, HFpEF is often underdiagnosed or misdiagnosed, delaying appropriate care..

因此，HFpEF 常常诊断不足或误诊，延误了适当的治疗。

The advanced capabilities of EchoGo® Heart Failure are designed to tackle these challenges. Leveraging deep learning algorithms, the platform generates a continuous risk score, offering greater granularity than binary outputs. This continuous scoring system allows for a more nuanced assessment of HFpEF likelihood, minimizing diagnostic uncertainty and enhancing clinical decision-making..

EchoGo® 心力衰竭的先进功能旨在应对这些挑战。通过利用深度学习算法，该平台生成连续的风险评分，提供比二元输出更高的精细度。这种连续评分系统可以对HFpEF可能性进行更细致的评估，减少诊断不确定性并增强临床决策能力。

New features of EchoGo® Heart Failure include:

EchoGo® 心力衰竭的新功能包括：

Probability-Based Scoring:

基于概率的评分：

The AI evaluates sequences of echocardiogram frames and assigns scores reflecting patterns consistent with HFpEF, providing valuable insights for clinical decision-making.

人工智能评估超声心动图帧序列，并给出与HFpEF一致的模式评分，为临床决策提供有价值的见解。

Uncertainty Estimates:

不确定性估计：

Each score is accompanied by an uncertainty estimate, ensuring that uncertain predictions are flagged for further review, reducing false positives or negatives.

每个评分都附有不确定性估计，确保不确定的预测被标记以供进一步审查，减少假阳性和假阴性。

Comparative Analysis Visualization:

对比分析可视化：

Clinicians can compare a patient's results against a large reference population of HFpEF and non-HFpEF cases, supporting objective and informed assessments.

临床医生可以将患者的结果与大量的HFpEF和非HFpEF病例的参考人群进行比较，从而支持客观且明智的评估。

EchoGo® Heart Failure with probability scoring is FDA Device Breakthrough cleared and is now available to healthcare professionals as part of the platform. For further information or to request a demonstration, visit

EchoGo® 心力衰竭概率评分系统已获得 FDA 突破性医疗器械认证，现作为平台的一部分提供给医疗专业人员。欲了解更多信息或申请演示，请访问

ultromics.com

。

About Ultromics

关于Ultromics

Ultromics is a pioneering health technology company founded at the

Ultromics 是一家成立于

University of Oxford

牛津大学

, UK, dedicated to transforming cardiac care through AI. Heart disease remains the world's leading cause of death, representing a global epidemic that demands urgent and innovative solutions. Ultromics collaborates with leading institutions such as Pfizer, Mayo Clinic, and Janssen Biotech, Inc. (a Johnson & Johnson Company) to develop groundbreaking diagnostic tools that improve the detection of heart disease worldwide.

英国，致力于通过人工智能转变心脏护理。心脏病仍然是全球死亡的主要原因，代表着一个需要紧急和创新解决方案的全球性流行病。Ultromics与辉瑞、梅奥诊所和杨森生物科技公司（强生公司旗下）等领先机构合作，开发突破性的诊断工具，以改善全球心脏病的检测。

With multiple FDA-cleared technologies, Ultromics continues to set new benchmarks for AI applications in cardiovascular imaging..

凭借多项FDA批准的技术，Ultromics继续为心血管成像领域的AI应用设立新标杆。

References

参考文献

1 - Akerman AP, Al-Roub N, Angell-James C, et al.. (2025). External validation of artificial intelligence for detection of heart failure with preserved ejection fraction. Nature Communications, 16, 2915.

1 - Akerman AP, Al-Roub N, Angell-James C, 等. (2025). 人工智能检测射血分数保留的心力衰竭的外部验证. 《自然通讯》, 16, 2915.

https

://

doi.org/10.1038/s41467-025-58283-7

。

Photo:

照片：

https://mma.prnewswire.com/media/2652711/Ultromics.jpg

SOURCE Ultromics

来源：Ultromics

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗